Myoscience, Inc.

Myoscience, Inc. develops innovative non-opioid pain relief solutions, utilizing advanced cold technology to provide effective pain management. The company focuses on addressing various pain conditions through its proprietary treatments. Myoscience, Inc.

is a company that specializes in advanced pain management technologies. Founded in 2005, it is headquartered in Fremont, US, and has undergone a strategic shift with its acquisition by Pacira Pharmaceuticals, Inc. in March 2019 for USD 120 mn, with an additional USD 100 mn contingent on achieving commercial and regulatory milestones. The founder's details are not specified, and the company has completed a total of 14 deals.

Myoscience, Inc. is recognized for its flagship product, iovera°, a revolutionary treatment that employs advanced cold technology to deliver immediate and long-lasting pain relief. This treatment specifically targets peripheral nerve tissue to disrupt pain signals, making it a viable option for patients suffering from osteoarthritis (OA) knee pain and those exploring alternatives to knee replacement surgery. iovera° is FDA-cleared, safe, and can be administered in a variety of healthcare settings, including outpatient departments and ambulatory surgery centers.

In addition to its knee applications, iovera° is also effective for pain relief in other regions such as the hip, shoulder, spine, foot, and ankle, and is indicated for conditions like rib fractures and post-mastectomy pain. The company serves a diverse range of clients, including healthcare providers and patients across the United States. Myoscience, Inc. generates revenue through the provision of iovera° and its associated services.

The revenue model is based on direct transactions with healthcare providers, who integrate iovera° into their pain management protocols. Hospitals and clinics purchase the iovera° system and consumables, allowing them to offer this non-opioid treatment to their patients. Pricing is generally determined per treatment session or device usage, reflecting the advanced nature of the technology and its clinical benefits. Relationships with healthcare facilities are characterized as Business-to-Business (B2B), enabling partnerships that facilitate patient access to effective pain management solutions.

Looking ahead, Myoscience, Inc. aims to leverage its recent acquisition by Pacira Pharmaceuticals, Inc. to enhance its product portfolio and expand market reach. This includes ongoing development of new pain relief products based on the iovera° technology.

The recent acquisition deal, finalized in March 2019, outlines an initial investment of USD 120 mn, with plans for further funding contingent upon achieving specific commercial and regulatory milestones. Additionally, Myoscience intends to broaden its market presence, particularly in the United States, to improve access to its non-opioid pain management solutions across various healthcare settings.